May 30 |
EC grants orphan medicinal product status to Rocket’s RP-A601
|
May 29 |
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
|
May 12 |
Cantor picks 14 undervalued biotech stocks worth a second look
|
May 10 |
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
|
May 7 |
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
|
May 6 |
Rocket Pharmaceuticals GAAP EPS of -$0.66 beats by $0.01
|
May 6 |
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
|
Apr 30 |
Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why
|
Apr 24 |
Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)?
|
Apr 5 |
Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)
|